144 related articles for article (PubMed ID: 27127618)
1. A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma.
Lopez JI; Cortes JM
F1000Res; 2016; 5():385. PubMed ID: 27127618
[TBL] [Abstract][Full Text] [Related]
2. Multisite tumor sampling enhances the detection of intratumor heterogeneity at all different temporal stages of tumor evolution.
Erramuzpe A; Cortés JM; López JI
Virchows Arch; 2018 Feb; 472(2):187-194. PubMed ID: 28842744
[TBL] [Abstract][Full Text] [Related]
3. Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC).
Guarch R; Cortés JM; Lawrie CH; López JI
F1000Res; 2016; 5():2020. PubMed ID: 27635226
[TBL] [Abstract][Full Text] [Related]
4. Detection of Intratumor Heterogeneity in Modern Pathology: A Multisite Tumor Sampling Perspective.
Cortés JM; de Petris G; López JI
Front Med (Lausanne); 2017; 4():25. PubMed ID: 28321395
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Tumor Eco-Evolution in Renal Cell Carcinoma Sampling.
López-Fernández E; López JI
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518081
[TBL] [Abstract][Full Text] [Related]
6. A multi-site cutting device implements efficiently the divide-and-conquer strategy in tumor sampling.
Lopez JI; Cortes JM
F1000Res; 2016; 5():1587. PubMed ID: 27540472
[TBL] [Abstract][Full Text] [Related]
7. Multisite tumor sampling: a new tumor selection method to enhance intratumor heterogeneity detection.
López JI; Cortés JM
Hum Pathol; 2017 Jun; 64():1-6. PubMed ID: 28237785
[TBL] [Abstract][Full Text] [Related]
8. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level.
Manini C; López-Fernández E; Lawrie CH; Laruelle A; Angulo JC; López JI
Curr Urol Rep; 2022 Jun; 23(6):93-97. PubMed ID: 35416538
[TBL] [Abstract][Full Text] [Related]
9. Intratumor heterogeneity in clear cell renal cell carcinoma: a review for the practicing pathologist.
López JI
APMIS; 2016 Mar; 124(3):153-9. PubMed ID: 26865355
[TBL] [Abstract][Full Text] [Related]
10. Towards Personalized Sampling in Clear Cell Renal Cell Carcinomas.
Manini C; López-Fernández E; López JI
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884442
[TBL] [Abstract][Full Text] [Related]
11. Discovering intratumor heterogeneity: the next frontier for pathologists.
López JI; De Petris G
Pathologica; 2017 Jun; 109(2):110-113. PubMed ID: 28748969
[TBL] [Abstract][Full Text] [Related]
12. Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma.
Ran X; Xiao J; Zhang Y; Teng H; Cheng F; Chen H; Zhang K; Sun Z
Ther Adv Med Oncol; 2020; 12():1758835920977117. PubMed ID: 33425025
[TBL] [Abstract][Full Text] [Related]
13. Precision sampling fuels precision oncology: an evolutionary perspective.
Manini C; López-Fernández E; López JI
Trends Cancer; 2021 Nov; 7(11):978-981. PubMed ID: 34493466
[TBL] [Abstract][Full Text] [Related]
14. Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.
López JI; Angulo JC
Curr Urol Rep; 2018 Jan; 19(1):3. PubMed ID: 29374850
[TBL] [Abstract][Full Text] [Related]
15. Snail heterogeneity in clear cell renal cell carcinoma.
Zaldumbide L; Erramuzpe A; Guarch R; Pulido R; Cortés JM; López JI
BMC Cancer; 2016 Mar; 16():194. PubMed ID: 26951092
[TBL] [Abstract][Full Text] [Related]
16. Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer.
Yang C; Zhang S; Cheng Z; Liu Z; Zhang L; Jiang K; Geng H; Qian R; Wang J; Huang X; Chen M; Li Z; Qin W; Xia Q; Kang X; Wang C; Hang H
Genome Med; 2022 Dec; 14(1):142. PubMed ID: 36527145
[TBL] [Abstract][Full Text] [Related]
17. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
Zhang LL; Kan M; Zhang MM; Yu SS; Xie HJ; Gu ZH; Wang HN; Zhao SX; Zhou GB; Song HD; Zheng CX
Int J Cancer; 2017 Jan; 140(1):103-108. PubMed ID: 27646734
[TBL] [Abstract][Full Text] [Related]
18. Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneity.
McBride M; Rida PC; Aneja R
Mol Aspects Med; 2015 Nov; 45():3-13. PubMed ID: 26024970
[TBL] [Abstract][Full Text] [Related]
19. Intratumor Heterogeneity as a Prognostic Factor in Solid Tumors: A Systematic Review and Meta-Analysis.
Yu T; Gao X; Zheng Z; Zhao X; Zhang S; Li C; Liu G
Front Oncol; 2021; 11():744064. PubMed ID: 34722299
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival.
Morris LG; Riaz N; Desrichard A; Şenbabaoğlu Y; Hakimi AA; Makarov V; Reis-Filho JS; Chan TA
Oncotarget; 2016 Mar; 7(9):10051-63. PubMed ID: 26840267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
